Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. by Türk, UÖ et al.
Turk Kardiyol Dern Ars 2020;48(3):289-303   doi: 10.5543/tkda.2020.16359
Current clinician perspective on non-vitamin K antagonist
oral anticoagulant use in challenging clinical cases
Zorlu atriyal fibrilasyon olgularında non-vitamin K antagonisti
oral antikoagülan kullanımına güncel klinik yaklaşımlar
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Objective: The evolution of non-vitamin K antagonist anticoag-
ulants (NOACs) has changed the horizon of stroke prevention in 
atrial fibrillation (SPAF). All 4 NOACs have been tested against 
dose-adjusted warfarin in well-designed, pivotal, phase III, ran-
domized, controlled trials (RCTs) and were approved by regulatory 
authorities for an SPAF indication. However, as traditional RCTs, 
these trials have important weaknesses, largely related to their 
complex structure and patient participation, which was limited by 
strict inclusion and extensive exclusion criteria. In the real world, 
however, clinicians are often faced with complex, multimorbid 
patients who are underrepresented in these RCTs. This article is 
based on a meeting report authored by 12 scientists studying atrial 
fibrillation (AF) in diverse ways who discussed the management of 
challenging AF cases that are underrepresented in pivotal NOAC 
trials.
Methods: An advisory board panel was convened to confer on 
management strategies for challenging AF cases. The article is 
derived from a summary of case presentations and the collabora-
tive discussions at the meeting.
Conclusion: This expert consensus of cardiologists aimed to de-
fine management strategies for challenging cases with patients 
who underrepresented in pivotal trials using case examples from 
their routine practice. Although strong evidence is lacking, ex-
ploratory subgroup analysis of phase III pivotal trials partially in-
forms the management of these patients. Clinical trials with higher 
external validity are needed to clarify areas of uncertainty. The 
lack of clear evidence about complex AF cases has pushed clini-
cians to manage patients based on clinical experience, including 
rare situations of off-label prescriptions.
Amaç: Non-Vitamin K antagonisti oral antikoagülanların (NOAK) 
geliştirilmesi ve yaygın klinik kullanıma girmesi ile Atriyal fibrilas-
yonda (AF) inmeden korunmanın ufku değişmiştir. Her ne kadar 
dört NOAK, büyük çaplı Faz 3 klinik denemeler ile düzenleyici 
otoritelerden alarak pazar erişim sürecini tamamlasa da Faz 3 
denemelerin eksternal validasyonuna ilişkin geleneksel zorluklar 
günlük pratikte klinisyenleri zorlu olgu ve klinik senaryolar ile kar-
şı karşıya bırakmaktadır. Günlük pratiklerinde klinisyenler, sıklıkla 
söz konusu Faz 3 denemelerde yeterince temsil edilmemiş ve 
yeterli kanıtın bulunmadığı hasta grupları ile yüz yüze kalmakta-
dır. Bu yazıda, pivot NOAK denemelerinde yeterince temsil edil-
meyen ancak günlük pratikte sıklıkla karşılaşılan AF olgularının 
yönetimi ile ilgili olarak, günlük pratikte bu AF olgularının takip ve 
tedavisini sürdüren 12 kardiyoloji akademisyeninin katıldığı top-
lantı raporu sunulmaktadır. 
Yöntemler: Zorlu AF olgularının yönetim stratejilerini tartışmak için 
bir danışma kurulu paneli toplanmıştır. Mevcut makale bu toplantı-
daki olgu sunumları ve tartışmaların özeti olarak derlenmiştir.
Sonuç: Kardiyologların bu uzman fikir birliği, rutin uygulamala-
rından olgu örnekleri kullanarak, önemli çalışmalarda yeterince 
temsil edilmeyen zorlu olguların yönetim stratejilerini tanımlamayı 
amaçlamıştır. Güçlü kanıtlar eksik olmakla birlikte, faz çalışmala-
rın alt grup analizleri, bu hastaların yönetimini hakkında kısmen 
bilgi vermektedir. Bununla birlikte alt grup analizlerinin hipotez 
kanıtlayıcı değil hipotez oluşturucu doğası unutulmamalı, ihtiyaç 
duyulan kanıtların elde edilmesine yönelik uygun tasarlanmış 
deneme/çalışmaların gerçekleştirilmesi gerekliliği göz önünde 
bulundurulmalıdır. Bu süreç, klinisyenlerin NOAK’ları yalnızca kli-
nik deneyimlerine dayanarak “off label” kullanmasının da önüne 
geçecektir.
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Atrial fibrillation (AF) is the most common car-diac arrhythmia and is associated with a 5-fold 
increased risk of ischemic stroke.[1] Approximately 1 
in 3 ischemic strokes are related to AF.[2] Furthermore, 
AF-related strokes are more severe and associated 
with higher risks of morbidity and mortality than non-
AF related strokes.[1] Therefore, stroke prevention is 
an essential element of AF management. 
Vitamin K antagonists (VKAs) reduce strokes by 
64% compared with no treatment and 39% compared 
with antiplatelet therapy.[3] However, sustaining the 
quality of anticoagulation control can be a challenging 
process. A therapeutic range (TTR) of >70% should 
be maintained to improve outcomes.[4] The evolu-
tion of non-vitamin K antagonist oral anticoagulants 
(NOACs), including dabigatran, rivaroxaban, apixaban 
and edoxaban, has changed the horizon of stroke pre-
vention in AF (SPAF). These agents have improved ef-
ficacy, safety, and convenience compared with VKAs. 
They are associated with a 50% relative risk reduction 
of intracranial hemorrhage compared with warfarin.[5]
All four NOACs have been tested against dose-ad-
justed warfarin in well-designed pivotal phase III ran-
domized controlled trials (RCTs) that included large 
numbers of AF patients. Consequently, the NOACs 
were approved by regulatory authorities for a SPAF 
indication. However, as traditional RCTs, these tri-
als have significant weaknesses, related primarily 
to their complex structure and patient participation, 
strict inclusion criteria, and extensive exclusion crite-
ria. Finally, their generalizability and external validity 
have been questioned.[6] In the real world, clinicians 
are often faced with complex, multi-morbid patients 
who were underrepresented in these RCTs. Therefore, 
therapeutic decisions are often challenging in routine 
clinical practice because evidence from RCTs is not 
available or is insufficient for selected subgroups of 
multi-morbid patients.
In real-world circumstances, given the large num-
ber of these patients, the management process in rou-
tine practice must be considered carefully. For clinical 
scenarios in which the formal evidence or guidelines 
do not provide clear conclusions, a consensus method 
may provide clinical guidance and management 
strategies.
This is the report of a meeting of cardiologists that 
was designed to address unanswered issues and com-
plex situations related 
to the management of 
challenging AF cases.
Methods
An advisory board 
panel was convened 
to discuss manage-
ment strategies for 
challenging AF cases. 
Twelve cardiologists 
from different health-
care providers (uni-
versity hospitals, state 
hospitals, and private 
practice) who are ex-
perts on AF partici-
pated in this meeting 
and discussed 8 cases. 
All of the participants 
shared information and opinions on recent advances 
in AF management, clinical trial results, guidelines, 
and other issues for each clinical scenario. This arti-
cle is derived from a summary of case presentations 
and the ensuing discussion at the meeting. All of the 
authors participated in the editing of the entire paper 
and each author contributing a case study had primary 
responsibility for that section.
Case 1
A 68-year-old woman presented at the cardiology 
department with fatigue and shortness of breath. Her 
medical history was significant for AF (CHA2DS2-
VASc score: 3, HASBLED score: 3, left ventricular 
ejection fraction [EF]: 65%) detected 1 year ear-
lier. The estimated creatinine clearance (CrCl) was 
38 mL/minute, which was comparable to stage 3b 
chronic kidney disease (CKD) (moderate reduction 
in kidney function). Warfarin therapy was initiated. 
Due to bleeding complications and high international 
normalized ratio (INR) values, fresh frozen plasma 
was administered on 2 occasions. Finally, labile INR 
values led to the initiation of NOAC treatment with 
rivaroxaban (15 mg/day). Her medications also in-
cluded metoprolol 50 mg once daily, furosemide 40 
mg once daily and a proton pump inhibitor (PPI).
After 2 months of follow-up, the patient presented 
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at the emergency department with dyspnea (acute pul-
monary edema) and reduced urine output. A laboratory 
assessment revealed a serum creatinine level of 6.3 
mg/dL. Her creatinine level remained high, prompt-
ing hemodialysis (HD) treatment (3 times per week). 
Rivaroxaban treatment was terminated, and warfarin 
therapy with close INR monitoring was reinitiated.
Evidence
Question 1: Should an anticoagulant be used in a pa-
tient with AF to prevent ischemic stroke, despite in-
creased bleeding risk on dialysis?
Question 2: If yes, which anticoagulation strategy 
should we choose? A vitamin K antagonist or a NOAC?
The risk of AF is greater in patients with CKD and 
end-stage renal disease (ESRD) who require dialysis. 
The prevalence of AF is 8% to 18% in the CKD pop-
ulation, 7% to 27% in patients treated with HD, and 
0.4% to 1.0% in the non-CKD general population.[7] 
The most common risk stratification scheme validated 
and suggested by current guidelines for predicting 
stroke in AF patients is the CHA2DS2-VASc score. 
The HAS-BLED risk score was developed to deter-
mine the risk of bleeding.
Our patient’s CHA2DS2-VASc score was 3, with 
an estimated risk of stroke of 3.2% per year. Her 
HAS-BLED score was 3, with an estimated risk of 
3.74 major bleeds per 100 patient-years. However, 
these scoring systems were developed and validated 
exclusively in patients not receiving dialysis; signifi-
cant components of the scores, such as hypertension, 
diabetes, and congestive heart failure in CHA2DS2-
VASc, may not reliably predict strokes in patients on 
dialysis.[8] In a study of 12,284 patients on dialysis 
in the United States, fewer than 10% of the patients 
had a CHA2DS2-VASc score under 2,
[9] indicating a 
low risk of ischemic stroke. Furthermore, recent stud-
ies have demonstrated that the CHADS2, CHA2DS2-
VASc,[10,11] and HAS-BLED[10] scores can predict is-
chemic strokes but not bleeding events in patients on 
dialysis.[10]
There are no RCT data on the use of warfarin to 
prevent ischemic-embolic stroke in patients with AF 
and on HD. Numerous observational studies have re-
ported conflicting results for VKA therapy regarding 
efficacy without a clear, consistent benefit in patients 
on dialysis.[7,8] Most studies have proved a signifi-
cantly lower incidence of stroke and embolism when 
warfarin was used, but also a markedly increased 
bleeding risk.[12,13] Studies have demonstrated that 
the risk of stroke is reduced when the TTR is >70%, 
but patients on dialysis receiving daily warfarin often 
have TTR of <50%.[14] Of note, the use of warfarin 
in patients on dialysis may result in calciphylaxis, a 
painful and often lethal condition caused by calcifi-
cation and occlusion of cutaneous arteries and arte-
rioles.[15]
In the US (but not in Europe) apixaban 5 mg twice 
daily and rivaroxaban 15 mg once a day are currently 
approved for chronic, stable, dialysis-dependent pa-
tients with dosing recommendations based on phar-
macokinetic and pharmacodynamic data. However, 
supratherapeutic plasma levels were recently demon-
strated with apixaban 5 mg twice daily.[16] Studies 
have reported NOAC doses in patients with ESRD or 
on dialysis of 2.5 mg twice daily for apixaban, 15 mg 
daily for edoxaban, and 15 mg or 10 mg daily for ri-
varoxaban.[17–19] It needs to be kept in mind that given 
the simultaneous lack of strong evidence for VKAs in 
this patient population, decisions related to anticoag-
ulation should be individualized. 
A recent retrospective cohort study of Medicare in-
surance beneficiaries in the USA sought to determine 
patterns of apixaban use and the associated outcomes 
in dialysis-dependent patients with ESRD and AF. 
The study results indicated that a standard 5 mg twice 
daily dose of apixaban was associated with a lower 
risk of major bleeding, and a reduction in thromboem-
bolism and mortality compared with warfarin.[20] This 
study was not discussed at the meeting because it was 
not yet published at the time.
Given all the considerations above, in this par-
ticular patient, the risks of bleeding were not much 
greater than the risk of ischemic-embolic stroke. 
Thus, warfarin therapy and close INR follow up was 
preferred. The board also discussed the potential use 
of a NOAC; however, the participants noted off-la-
bel use and the lack of strong evidence in this kind of 
population.
Areas of uncertainty
The efficacy and safety of NOACs in patients with 
ESRD and on dialysis are unclear and an important 
subject for additional study. The major problem in 
assessing the effectiveness of anticoagulants in CKD 
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and pharmacodynamic profiles. In addition, monitor-
ing of the anticoagulation level is not required.[19] As a 
result of these properties, NOACs are widely used in 
patients with AF to prevent ischemic-embolic stroke 
and systemic embolism. 
Some warfarin-treated patients experience an ac-
celerated progression of CKD and acute kidney in-
jury associated with excessive anticoagulation, so-
called warfarin-related nephropathy.[24,25] In contrast, 
NOACs, particularly dabigatran and rivaroxaban, 
may be associated with lower risks of adverse renal 
outcomes than warfarin.[26] Patients with AF and mod-
erate renal insufficiency have higher rates of stroke 
and bleeding than those with normal renal function. 
Compared with warfarin, all 4 NOACs have demon-
strated consistent efficacy and safety in patients with 
mild to moderate CKD compared with non-CKD pa-
tients in the respective subgroup analyses of pivotal 
NOAC trials.[27–30]
Careful adjustment of the NOAC dose is crucial 
in patients with CKD. While rivaroxaban, edoxaban, 
and apixaban (with additional dose reduction criteria) 
doses were reduced according to renal function in the 
respective RCT, patients in the RE-LY trial (Random-
ized Evaluation of Long Term Anticoagulant Ther-
apy) were randomized to dabigatran 150 mg twice 
daily or 110 mg twice daily without dose reduction 
for renal insufficiency.
Rivaroxaban, an extensively studied anticoag-
ulant in registration trials, is one of the most pre-
ferred agents for CKD patients. The ROCKET AF 
trial (Rivaroxaban Once Daily Oral Direct Factor 
Xa Inhibition Compared with Vitamin K Antago-
nism for Prevention of Stroke and Embolism Trial 
in Atrial Fibrillation) compared rivaroxaban with 
warfarin for the prevention of all stroke and systemic 
embolism events in 14,264 patients with AF.[31] The 
dose of rivaroxaban was reduced from 20 to 15 mg 
daily in patients with moderate renal dysfunction 
(Cockcroft-Gault CrCl: 30–49 mL/minute at base-
line; 20.7% of the trial cohort), based on extensive 
pharmacodynamic data and pharmacokinetic model-
ing. In the ROCKET trial, there were no further dose 
adjustments after the baseline correction for CrCl.[29] 
Rivaroxaban is the only NOAC for which a specific 
dose has been tested prospectively in patients with 
CKD (CrCl 15–49 mL/minute). Pre-specified sub-
group analysis revealed that dose adjustment yielded 
patients is that those with advanced stages of CKD 
have been excluded from phase III pivotal trials. 
Left atrial appendage occlusion (LAAO) has 
emerged as an alternative mechanical approach to oral 
anticoagulation in AF patients.[21] European guidelines 
have recommended LAAO in patients with AF and 
contraindications for long-term anticoagulation (class 
IIb indication, level of evidence B).[22] However, there 
is a lack of evidence of the effectiveness of LAAO 
in chronic dialysis patients with AF. A retrospective 
study from a single center was designed to provide 
data regarding the safety and efficacy of LAAO using 
the WATCHMAN LAA system (Atritech, Plymouth, 
MN, USA) in AF patients with CKD.[23] The device 
was found to be safe and effective in preventing stroke 
in AF patients with CKD. However, no randomized, 
prospective trial has been performed to date.
Advisory board recommendation
Following a discussion period, the participants agreed 
with the cessation of rivaroxaban and continuing 
VKA treatment. Footnote: Recently, the US Food and 
Drug Administration has included labeling related to 
the use of rivaroxaban (as well as apixaban) for pa-
tients on HD. 
Case 2
A 73-year-old female patient with a history of parox-
ysmal AF and hypertension was referred to the clinic 
due to deterioration of kidney function (creatinine: 1.3 
mg/dL; CrCl: 35 mL/minute). Her kidney function had 
been within normal limits 1 month prior (creatinine: 
0.8 mg/dL; CrCl: 55 mL/minute). The medications in 
use were rivaroxaban 20 mg once daily, amiodarone 
200 mg once daily, and ramipril/hydrochlorothiazide 
combination 5/12.5 mg once daily. In her history, she 
had fallen 1 week earlier and had soft tissue trauma, 
for which she had used an analgesic. She terminated 
use of the analgesic 3 days before being seen. Her 
family physician had detected worsening of her re-
nal function and referred her to the cardiologist for a 
NOAC dose evaluation.
Evidence
In recent years, there has been a surge in NOACs 
approved for the prevention and treatment of throm-
boembolic disorders. NOACs have many advantages 
over warfarin, such as predictable pharmacokinetic 
results comparable with the overall trial results.[32] 
Case solution
The deterioration of renal function was considered 
to be a temporary effect of the analgesic use and the 
dose of rivaroxaban was not reduced. An outpatient 
visit was planned for 1 month later to reassess renal 
function, and the laboratory evaluation from that visit 
revealed normalization of renal function. The patient 
had not reported any bleeding event during follow-up. 
We also recommended that the patient should avoid 
dehydration and further use of analgesics.
Areas of uncertainty
There is a lack of data on the real effectiveness and 
safety in specific high-risk populations, such as CKD 
patients. Patients with advanced stages of CKD have 
often been excluded from landmark NOAC trials due 
to the variable degree of renal drug clearance and risk 
of drug overdosage.[28]
Advisory board recommendation
After discussion, the board agreed with a reduction of 
rivaroxaban to 15 mg for this patient. However, the 
participants emphasized the possibility of increased 
ischemic events with suboptimal anticoagulation and 
agreed to titrating the NOAC dose according to fol-
low-up CrCl values. 
Case 3
An 80-year-old woman with persistent AF (CHA2DS2-
VASc 4) had been receiving rivaroxaban for 5 years. 
She had also been taking amiodarone and metopro-
lol for years. The patient was admitted to the emer-
gency department experiencing malaise and diarrhea. 
Three days before admission, ampicillin treatment 
had been initiated for a resistant upper respiratory 
tract infection. Biochemical analysis revealed an el-
evated serum creatinine measurement of 3 mg/dL 
and a serum urea value of 130 mg/dL (CrCl: 15 mL/
minute). The patient’s urine output decreased (100-
200 mL/day). Intravenous furosemide treatment was 
administered, and close follow-up was recommended 
by the nephrologist. Her anticoagulant treatment was 
replaced with warfarin. On the third day of hospi-
talization, her urine output increased, and the serum 
creatinine level progressively declined. She was dis-
charged on the seventh day with the medications of 
warfarin, amiodarone, and amlodipine.
Evidence
AF is the most common arrhythmia encountered in 
clinical practice, and the prevalence increases with 
advancing age, rising from <1% in persons aged 
55–59 years to >10% in those aged ≥85 years.[33] In 
clinical trials, warfarin effectively reduced the risk 
for ischemic stroke associated with AF.[34] Significant 
drawbacks of warfarin include drug-food and drug-
drug interactions, and a narrow therapeutic window. 
For this reason, frequent monitoring of the anticoag-
ulation level in the elderly is important. Warfarin is 
underutilized in older patients who face the highest 
risk of ischemic events.
NOACs provide an alternative to warfarin as 
oral anticoagulation for AF. Four landmark trials of 
NOACs have enrolled significant populations of older 
people (defined as ≥75 years) ranging from 31% to 
44% in the individual trials.[35] 
Meta-analyses of NOAC trial data suggest no in-
teraction with age for safety and efficacy, with the 
exception of dabigatran.[5] There was a significant 
interaction between age and increased major ex-
tracranial bleeding with both doses of dabigatran 
used in the RE-LY trial. Conversely, no significant 
difference in the rate of major extracranial bleeding 
was seen based on age with apixaban, edoxaban, or 
rivaroxaban compared with the overall trial results.
[35] Importantly, the greater absolute risk resulted in a 
greater risk reduction when using NOACs instead of 
a VKA in these older patients, resulting in a need to 
treat fewer of these patients compared with younger 
patients.
Areas of uncertainty 
Very elderly patients (defined ≥80 years) are often 
under-represented in pivotal NOAC trials. However, 
recent retrospective database studies have assessed 
the real-world effectiveness and safety of NOACs. A 
study from Japan enrolled 1339 patients from 8 hos-
pitals.[36] The patients were divided into 2 groups ac-
cording to age: the very elderly group (453 patients, 
aged ≥80 years) and the control group (886 patients, 
aged <80 years). The results indicated that rivaroxa-
ban 10 mg daily was effective and safe in very elderly 
patients with AF. 
Coleman et al.[37] performed a retrospective study 
using data from the US Truven Health MarketScan 
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of ticagrelor in patients treated with NOAC.
Evidence
Approximately 6% to 8% of patients who undergo 
coronary stent implantation also have AF.[38] Dual an-
tiplatelet therapy (DAPT) with a P2Y12 inhibitor plus 
aspirin is superior to a VKA in patients who undergo 
PCI with stent implantation, but among patients with 
AF, a VKA is superior to DAPT for the prevention of 
stroke and systemic embolism.[39,40] As a result, ther-
apy with DAPT and a VKA (triple therapy) is gener-
ally considered the standard of care for patients who 
have both a stent and AF.[41] However, studies have 
shown that these regimens are associated with a 3- 
to 4-fold increased risk of bleeding complications.[42] 
Current guidelines recommend shortening the dura-
tion of triple therapy and using individualized man-
agement for each patient with consideration given to 
ischemic and bleeding risks.
Three recently published RCTs compared NOACs 
to a VKA in terms of safety (i.e., bleeding) in a vari-
ety of combinations with 1 or 2 antiplatelet agents. 
In the PIONEER AF-PCI study (A Study Exploring 
Two Strategies of Rivaroxaban and One of Oral Vita-
min K Antagonist in Patients With Atrial Fibrillation 
Who Undergo Percutaneous Coronary Intervention), 
2 different rivaroxaban regimens were compared with 
standard triple therapy with a VKA and DAPT in 
2124 stented subjects with AF: a low-dose of rivarox-
aban 15 mg (10 mg in patients with CrCl: 30–50 mL/
minute) with a P2Y12 inhibitor and a very low dose 
of rivaroxaban of 2.5 mg twice daily combined with 
aspirin and a P2Y12 inhibitor.[43] The PIONEER AF-
PCI study revealed that both rivaroxaban arms were 
associated with a lower rate of clinically significant 
bleeding than VKA therapy plus DAPT at 1, 6, and 
12 months.
The RE-DUAL PCI study (Randomized Evalua-
tion of Dual Therapy With Dabigatran vs. Triple Ther-
apy With Warfarin in Patients With AF That Undergo 
a PCI With Stenting) compared the safety of dual-
antithrombotic therapy that included dabigatran at 2 
different doses (110 mg twice daily or 150 mg twice 
daily) in combination with clopidogrel or ticagrelor 
(i.e., dual therapy, without aspirin) with standard triple 
therapy (for 1 or 3 months, depending on the type of 
stent) with a VKA, aspirin, and either clopidogrel or 
ticagrelor in 2725 patients with AF who underwent 
Research Database (IBM Corp., Armonk, NY, USA) 
from November 2011 to March 2016 to assess the 
real-world effectiveness and safety of rivaroxaban 
vs warfarin in nonvalvular atrial fibrillation patients 
aged ≥80 years. The study results showed consistent 
effectiveness and safety for rivaroxaban vs warfarin, 
as reported in the ROCKET-AF trial.[32]
Finally, although NOACs have fewer drug-drug 
interactions compared with VKAs, a possible phar-
macokinetic interaction between rivaroxaban and 
amiodarone is possible in this case.
Advisory board recommendation
The board agreed with initiation of rivaroxaban 15 mg 
daily. The members specified the high elderly patient 
representation ratio in the ROCKET-AF Trial as the 
reason (43% of overall population older than 75 years 
of age).
Case 4
A 60-year-old man was referred to the hospital with 
chest pain and shortness of breath. He had a medical 
history of diabetes mellitus and paroxysmal AF. He 
was diagnosed with myocardial infarction, as his elec-
trocardiogram results showed pathological Q waves 
and ST-segment elevation in the precordial leads. He 
had been treated with insulin, oral antidiabetics, a 
PPI, and a NOAC (rivaroxaban 20 mg) for 2 years. 
Previously, he had received warfarin; however, his 
INR level remained unstable, which led to replace-
ment with a NOAC.
Anticoagulant use was terminated temporarily. A 
loading dose of aspirin 300 mg followed by 100 mg 
daily, and a loading dose of ticagrelor 180 mg, fol-
lowed by 180 mg daily was administered, and coro-
nary angiography was planned (before transfer to our 
center). A second-generation drug-eluting stent was 
implanted when it became clear that this diabetic pa-
tient suffered from a long lesion in the left anterior 
descending artery. After the intervention, the patient 
remained in the intensive care unit for 2 days and 
rivaroxaban was restarted. On the fifth day after the 
percutaneous coronary intervention (PCI), the patient 
was discharged with the combination of aspirin 100 
mg, clopidogrel 75 mg, rivaroxaban 15 mg, atorvas-
tatin 80 mg, metoprolol 50 mg, ramipril 5 mg, and a 
PPI. Ticagrelor was replaced with clopidogrel due to 
the lack of safety and efficacy data related to the use 
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provided an update on dual antiplatelet therapy in 
the coronary artery disease guidelines to recommend 
rivaroxaban 15 mg once a day in combination with 
aspirin and/or clopidogrel based on the PIONEER 
data.[47] The guideline also recommended the use of 
the lowest tested NOAC dose effective for stroke 
prevention in AF in combination with aspirin and/or 
clopidogrel.
Areas of uncertainty 
There was an insufficient number of patients on more 
powerful P2Y12 inhibitors (ticagrelor or prasugrel) 
for efficacy evaluation in both the PIONEER AF-PCI 
trial and the RE-DUAL PCI trial. Also, these trials 
evaluated the safety of these NOACs with the primary 
outcome of major bleeding. 
It remains unknown whether dual therapy (i.e., 
rivaroxaban 15 mg daily or dabigatran 110/150 mg 
twice daily in combination with a P2Y12 inhibitor) 
sufficiently protects against stroke prevention (ri-
varoxaban), stent thrombosis, or myocardial infarc-
tion, due to underpowered clinical trials.
Advisory board recommendation
After discussion of the case, the authors agreed 
with replacing ticagrelor with clopidogrel. They also 
agreed to continuing triple therapy up to 6 months, as 
a patient had a high thromboembolic risk.
Case 5
A 72-year-old hypertensive female with a 1.5-year his-
tory of persistent AF managed with warfarin therapy 
and moderate anticoagulation control (TTR: 65%). 
Her medications also included diltiazem 90 mg, val-
sartan/hydrochlorothiazide 160/12.5 mg and a PPI. 
The patient presented at the emergency department 
with sudden-onset left-sided weakness. Brain mag-
netic resonance imaging revealed an ischemic area in 
the right temporoparietal region, but no evidence of 
bleeding was observed. A duplex carotid scan was neg-
ative for stenosis of both extracranial carotid arteries, 
and transthoracic echocardiography revealed mild left 
ventricular hypertrophy, left atrial enlargement, and an 
EF within normal limits. The CHA2DS2-VASc score 
was 5 and the HASBLED score was 3. The National 
Institutes of Health Stroke Scale (NIHSS) score was 
10, which determines the severity of neurological ef-
fect and planned medical treatment in stroke patients. 
PCI.[44] The composite of major or clinically relevant 
non-major bleeding events and major bleeding events 
alone were significantly reduced in the 110 mg and 
150 mg dabigatran dual therapy arms compared with 
the standard VKA triple therapy arm.
The AUGUSTUS trial (Aspirin Placebo in Patients 
with Atrial Fibrillation and Acute Coronary Syndrome 
or Percutaneous Coronary Intervention) enrolled pa-
tients with both AF and recent acute coronary syn-
drome or PCI who went on a P2Y12 inhibitor, most 
often clopidogrel. The incidence of major bleeding, 
death, or hospitalization was lower with apixaban use 
than a VKA, such as warfarin.[45] The primary outcome 
was major or clinically relevant non-major bleeding. 
At 6 months, the antithrombotic regimen that included 
apixaban without aspirin resulted in less bleeding and 
fewer hospitalizations without significant differences 
in the incidence of ischemic events than regimens 
that included a VKA, aspirin, or both. Whereas the 
AUGUSTUS trial allowed a stabilization period of up 
to 14 days between acute coronary syndrome or PCI 
and randomization (mean: 6.6 days), which is the pe-
riod of highest risk for coronary ischemic events, in 
the PIONEER AF-PCI trial, randomization occurred 
within 72 hours after sheath removal. Recently, the 
ENTRUST-AF PCI trial (Edoxaban Treatment Versus 
Vitamin K Antagonist in Patients With Atrial Fibril-
lation Undergoing Percutaneous Coronary Interven-
tion) evaluated edoxaban treatment in combination 
with P2Y12 inhibition in AF patients who had under-
gone PCI.[46] In this open-label, non-inferiority trial, 
1506 patients were randomized after PCI to one of 
2 arms: edoxaban (60 mg once daily) plus a P2Y12 
inhibitor for 12 months or a VKA in combination with 
a P2Y12 inhibitor and aspirin (100 mg once daily, for 
1-12 months). The primary endpoint was defined as a 
composite of major or clinically relevant non-major 
bleeding within a year. The results showed that the 
edoxaban-based regimen was non-inferior for bleed-
ing compared with the VKA-based regimen, without 
significant differences in efficacy. The AUGUSTUS 
and ENTRUST-AF PCI trials were not discussed at 
this meeting because the findings were not published 
at that time.
Based on these trials, dual therapy with only a 
NOAC and a P2Y12 inhibitor is an alternative to 
triple treatment within 1–7 days after the acute phase. 
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[54] Current guidelines suggest initiating anticoagula-
tion in AF patients 1–14 days after an ischemic stroke, 
depending on stroke severity.[55]
Advisory board recommendation
The authors agreed with initiation of a NOAC in pa-
tients with a history of ischemic stroke under war-
farin therapy. Although the decision is not evidence-
based, a current European Heart Rhythm Association 
(EHRA) consensus paper has suggested this approach 
as an expert opinion.[55]
Case 6
A 62-year-old woman presented with AF, hypertension 
and type 2 diabetes mellitus. She had been suffering 
from fatigue, shortness of breath, and a decreased abil-
ity to exercise for the previous 3 months. All efforts to 
restore sinus rhythm with antiarrhythmic drugs were 
unsuccessful. Rivaroxaban 20 mg/day, ramipril 10 mg/
day, and metformin 2000 mg/day were administered. 
It was decided to perform catheter ablation, and the 
patient was hospitalized for the procedure. Transtho-
racic echocardiography revealed left atrial enlarge-
ment (49 mm), and 35% left ventricular EF.
Evidence
Catheter ablation is a well-established treatment to 
restore normal sinus rhythm in patients with symp-
tomatic AF.[56] This procedure has the risk of serious 
bleeding secondary to trans-septal puncture or exten-
sive manipulation and ablation in the left atrium. Left 
atrial catheter ablation provokes a prothrombotic con-
dition, increasing the risk of periprocedural throm-
boembolism.
The traditional anticoagulation approach was an 
interruption of oral VKA therapy and the use of hep-
arin bridging. However, the results of a non-random-
ized,[57] as well as a randomized study,[58] have revealed 
that performing AF ablation with uninterrupted anti-
coagulation may be safer and more effective. Since 
then, randomized[59–61] studies have compared the use 
of NOACs with no or minimal interruption to uninter-
rupted warfarin at the time of AF ablation. The results 
showed that NOACs were associated with a very low 
rate of ischemic events, and a similar or lower rate 
of bleeding complications than uninterrupted war-
farin. Recently, results from the ELIMINATE AF trial 
(Edoxaban Treatment Versus Vitamin K Antagonist 
Hemorrhagic transformation was not detected on cra-
nial computed tomography imaging on the fifth day.
Evidence
AF patients with a history of transient ischemic attack 
(TIA) or ischemic stroke are at an increased risk of 
recurrent stroke and major bleeding.[48]
The clinical objective includes reducing early and 
late recurrences without increasing the risk of major 
bleeding in patients suffering from AF-related stroke. 
The optimal timing to administer NOACs in patients 
with acute ischemic stroke and AF is uncertain. Each 
of the landmark phase III NOAC trials performed sub-
group analyses of patients based on a previous history 
of stroke or TIA. Results of these subgroup analyses 
were consistent with those of patients without previ-
ous stroke or TIA.[49–51]
Coleman et al.[52] performed a retrospective claims 
database study using records from the US Truven 
Health MarketScan Research Database (IBM Corp., 
Armonk, NY, USA) from January 2012 to June 2015. 
This study showed that the results for apixaban, dabi-
gatran, and rivaroxaban use in patients with nonva-
lvular atrial fibrillation with prior ischemic stroke/
TIA managed in real-world settings were relatively 
consistent with those of pivotal phase III RCTs.
Areas of uncertainty 
There is no evidence from RCTs to suggest that it 
is preferable to switch from VKA therapy to a NOAC 
or from one NOAC to another in previously antico-
agulated patients who suffer an ischemic stroke. In 
addition, there are no substantial study data to inform 
the optimal timing to reinstitute oral anticoagulation 
using a NOAC after TIA or stroke in AF patients, as 
Phase III trials excluded patients within 7–30 days 
after stroke.[6] The RAF study (Early Recurrence and 
Cerebral Bleeding in Patients with Acute Ischemic 
Stroke and Atrial Fibrillation) findings indicated that 
the best time to initiate anticoagulation treatment for 
secondary stroke prevention is 4–14 days from stroke 
onset. Furthermore, patients treated with oral antico-
agulants alone had better outcomes compared with 
patients treated with low molecular weight heparins 
alone or prior to oral anticoagulants.[53] The study re-
ported that NOACs (dabigatran, rivaroxaban, or apix-
aban) could be used within 2 weeks from stroke onset, 
given a seemingly acceptable risk of severe bleeding.
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John’s wort oil for a week.
Evidence
AF prevalence increases with advancing age.[33] In el-
derly patients, AF is often accompanied by a range 
of comorbidities. These patients commonly use 
more than 5 drugs, which constitutes polypharmacy. 
Polypharmacy has been associated with a higher risk 
of death and bleeding complications, particularly in 
anticoagulated patients. Also, polypharmacy has been 
associated with more disability, increased frequency 
of hospitalization, longer hospital stays, and more in-
hospital deaths.[64]
Warfarin, the most widely used oral anticoagulant, 
has multiple drug-drug interactions, often requires 
dose adjustments, and has a narrow therapeutic win-
dow. NOACs provide an alternative to warfarin for 
oral anticoagulation for AF. NOACs have fewer food 
and drug interactions than warfarin. However, special 
care is needed regarding the use of NOACs in patients 
with polypharmacy.
Recent studies have examined the effects of 
NOACs in patients with polypharmacy. Post-hoc 
analysis of the ARISTOTLE trial showed that patients 
concomitantly taking several (≥5 or ≥9) medications 
experienced similar outcomes and consistent treat-
ment effects with apixaban relative to warfarin.[65] 
Piccini et al.[66] examined the prevalence of polyphar-
macy and the impact of concomitant medications on 
ischemic and hemorrhagic events in patients taking 
rivaroxaban. This study showed that polypharmacy 
was associated with a higher risk of bleeding, but not 
stroke. Rivaroxaban was tolerated across complex pa-
tients on multiple medications.
The clearance of rivaroxaban is largely attributed 
to CYP3A4 and P-glycoprotein, both of which are 
subject to inhibition or induction by some drugs. 
Coadministration of rivaroxaban with strong in-
hibitors of both CYP3A4 and P-glycoprotein, in-
cluding ritonavir, ketoconazole, itraconazole, par-
conazole, and clarithromycin, is not recommended. 
Many patients with AF take antiarrhythmic drugs. 
Rivaroxaban has a few interactions with some an-
tiarrhythmics (amiodarone, dronedarone, and quini-
dine), and no interaction with digoxin, diltiazem, or 
verapamil.[54] Coadministration of rivaroxaban with 
dronedarone should be avoided.
[VKA] in Patients With Atrial Fibrillation [AF] Un-
dergoing Catheter Ablation) demonstrated that edox-
aban treatment represented a safe alternative to VKA 
therapy.[62]
Current guidelines recommend performing left 
atrial catheter ablation under uninterrupted anticoag-
ulant treatment.[63]
Areas of uncertainty
Whether opting to administer the last NOAC dose 
shortly before the procedure (i.e., truly uninterrupted) 
or to use a short cessation period (last NOAC dose 
on the day before the procedure), depends on several 
factors, including renal function, the CHA2DS2-VASc 
score, the experience of the operator, and the routine 
practice of intra-procedural heparin administration 
prior to the (first) trans-septal puncture.
Case solution
Catheter ablation was performed under uninterrupted 
rivaroxaban treatment (last rivaroxaban dose was on 
the day before the procedure). During the ablation, 
intravenous heparin was administered to achieve an 
activated clotting time of 300–350 seconds. The pa-
tient was discharged the next day. After 1 month, the 
patient’s symptoms had been relieved, and echocar-
diography revealed an improved EF of 50%.
Advisory board recommendation
The board members agreed with performing catheter 
ablation under uninterrupted anticoagulant treatment 
(target INR: 2–3). The authors recommended that 
there is no need to interrupt NOAC therapy before 
ablation.
Case 7
An 80-year-old diabetic male with a history of AF 
and CKD (CrCl: 41.7 mL/minute) presented at the 
outpatient clinic with macroscopic hematuria. The 
medication in use was rivaroxaban 15 mg/day, biso-
prolol 5 mg/day, ramipril 2.5 mg/day, and gliclazide 
60 mg/day. A urological examination and imaging 
tests were normal. When the patient was questioned 
in more detail, he mentioned that 5 days previously, 
clarithromycin had been initiated by the family 
physician for an upper respiratory tract infection 
and omeprazole for dyspeptic symptoms. He had 
also treated himself with Omega 3 capsules and St. 
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On admission, his blood pressure was 138/72 
mmHg and he had an irregular pulse. Electrocardio-
graphy revealed AF. After a neurology consultation, 
recombinant tissue plasminogen activator was admin-
istered intravenously. On the 15th day of admission, 
patient was discharged with neurological sequelae 
(NIHSS score: 6). Warfarin therapy was prescribed 
for secondary stroke prevention. Due to the patient’s 
neurological sequelae and difficulties with mobiliza-
tion, he could not attend his scheduled INR visits. 
Two months later, the patient fell and presented at the 
emergency department with an acute headache. Com-
puted tomography of the brain revealed a subdural 
hematoma. At that time, his INR level measured 3.5. 
The patient underwent an urgent surgical evacuation 
of the hematoma. On the third day after the opera-
tion, a left middle cerebral artery infarct developed. 
The patient was discharged from the hospital on the 
20th day from admission in a quadriplegic state. Six 
months later, the patient died from sepsis caused by 
pneumonia and decubitus ulcers.
Evidence
According to the current drug reimbursement policy 
of Turkey, reimbursement of NOAC therapy requires 
a warfarin “challenge” process. The process applies 
to patients who have failed to achieve a sufficient 
TTR (targeted INR level not successfully maintained 
between 2–3 in at least 3 of the last 5 measurements 
Case solution
Considering the potential drug interactions through 
CYP3A4 inhibition, the use of clarithromycin and 
St. John’s wort oil was terminated. The hematuria 
resolved in 2 days. The follow-up treatment was ri-
varoxaban 15 mg/day.
Advisory board recommendation
The authors discussed the potential pharmacokinetic 
and pharmacodynamic interactions between NOACs 
and concomitant medications/supplements. A recent 
EHRA consensus paper on NOACs has been detailed 
these interactions and summarized the results in col-
or-coded tables.[55] Remembering the interactions in 
routine clinical practice can be difficult for the clini-
cian; these user-friendly tables may help to overcome 
this challenge. Finally, the board advised the use of 
rivaroxaban or apixaban treatment according to con-
comitant medications/supplements.
Case 8
A 79-year-old male presented at the emergency de-
partment with sudden-onset left-sided weakness and 
slurred speech (NIHSS score: 15). Brain magnetic res-
onance imaging revealed acute ischemic infarction in 
the region of the right middle cerebral artery. His med-
ical history included a previous myocardial infarction. 
Table 1. Reimbursement policy examples from 2 countries 
Countries where NOACs are reimbursed Reimbursement conditions for stroke prevention
directly in SPAF patients
Finland Reimbursement with statement from physician to social insurance:
 1. Patients with CHA2DS2-VASc ≥2
 2. Patients with CHA2DS2-VASc = 1 and are not in good
  treatment balance (TTR <70% after 3 months) 
 3. Patients with CHA2DS2-VASc = 1 and warfarin is contraindicated  
  or causes adverse events. 
 Reimbursement with prescription note only:
 4. Cardioversion patients with CHA2DS2-VASc = 1 for max 3 months
Italy Reimbursed to prevent stroke and systemic embolism in patients  
 with NVAF with the following restrictions: Permanent NVAF
 • CHA2DS2-VASc >3 
 • HAS-BLED >3
NOAC: Non-Vitamin K antagonist oral anticoagulant; NVAF: Non-valvular atrial fibrillation; SPAF: Stroke prevention in AF.
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tive that the reimbursement condition is determined ac-
cording to the risk of stroke instead of failure to meet 
a mandatory initial warfarin challenge. Most of the 
medical treatment guidelines in Finland are also being 
taken as a reference by the Turkish Ministry of Health. 
The reimbursement conditions which enable first line 
access to NOAC therapy for patients with a high risk of 
stroke in Finland and Italy are shown Table 1.
Warfarin therapy requires frequent INR monitor-
ing, especially in elderly patients. For patients under 
warfarin therapy in Turkey, it is necessary present at 
a facility for a healthcare provider to perform the INR 
test. Factors such as transportation and mobilization 
are important to access. In cases with mobilization 
difficulties, such as those with a stroke history, the 
TTR frequently cannot be kept within the targeted 
limits. The quality of anticoagulation control is usu-
ally quantified by the average TTR, and a TTR of 
>70% is recommended.[67] At the same time, however, 
recorded in a 1-week interval after using warfarin for 
at least 2 months) or, in AF patients. have sustained 
ischemic stroke under VKA therapy. Unlike in AF, 
NOACs can be initiated directly in certain venous 
thromboembolism (VTE) patient groups (recurrent 
idiopathic pulmonary embolism or homozygous 
thrombophilia or active cancer patients with previous 
VTE or those who are immobilized). 
There are different reimbursement policies for 
NOAC therapy around Europe; in most countries 
NOACs are reimbursed as first line therapy. Pharma-
ceutical pricing in Turkey is performed based on the in-
ternational reference pricing system. Reference coun-
tries have similar conditions regarding access to health 
services. When reference countries are evaluated re-
garding reimbursement conditions, NOAC therapy is 
reimbursed first line in Greece, Portugal, and France. 
However, it is second line in Italy and Spain, as in 
Turkey, but with a very important, different perspec-
Table 2. Summary chart of advisory board opinions
Oral anticoagulant therapy in patients with a CrCl of • NOAC should not prescribed
15 mL/min and on dialysis 
Usage in worsening kidney function* • Rivaroxaban, apixaban, and edoxaban
NOAC use in very elderly patients (defined ≥80 years)** • Low dose of NOAC should be preferred (except dabigatran)
NOAC preference in combination with DAPT • Rivaroxaban 15 mg
(ASA+clopidogrel) • Dabigatran 110 mg
 • Apixaban 5 mg
In patients with a history of ischemic stroke under • Start NOAC (rivaroxaban)#
warfarin therapy
Continue NOAC before catheter ablation • NOAC should continue
Preference of NOAC in combination with • Rivaroxaban, apixaban
antiarrhythmic drugs • Dabigatran, edoxaban
Initiation of NOACs • Start NOAC directly as OAC in AF patients
 • Initiate NOAC in home care and/or immobile patients with AF
 • Initiate NOAC in prior stroke patients with AF
 • Initiate NOAC in cancer patients with AF
*Rivaroxaban, apixaban, and edoxaban (but not dabigatran) are approved in Europe for use in patients with severe chronic kidney disease (Stage 4, i.e., 
a creatinine clearance level of 15-29mL/minute), with a reduced dose regimen (according to defined criteria in the summary of product characteristics for 
apixaban) (50).
**Subgroup analysis revealed a significant interaction between age and increased extracranial major bleeding with dabigatran doses of 150 mg twice daily or 
110 mg twice daily in the RE-LY trial. Conversely, no significant interaction was seen between age and the rate of extracranial major bleeding with apixaban, 
edoxaban, or rivaroxaban compared with the overall trial results (50).
#Rivaroxaban is the most preferred option according to advisory board voting since the ROCKET trial provided more data in this patient population and there 
are real-word data confirming the results.
Red: Contraindicated/not recommended. Yellow: Cautionary use.
AF: Atrial fibrillation; ASA: Acetylsalicylic acid; DAPT: Dual antiplatelet therapy; OAC: Oral anticoagulant; NOAC: Non-Vitamin K antagonist oral anticoagu-
lant; NVAF: Non-valvular atrial fibrillation; SPAF: Stroke prevention in AF.
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it needs to be kept in mind that even being within the 
therapeutic range does not protect the patient from 
bleeding events. NOACs provide an oral anticoagu-
lation alternative to warfarin for AF. Four landmark 
trials of NOACs have revealed that NOACs were at 
least as effective as VKAs and were associated with 
less bleeding, particularly less intracerebral hemor-
rhage.[68] In our case, if NOAC therapy had been initi-
ated directly instead of warfarin, the intracranial hem-
orrhage risk would have been significantly decreased, 
and INR monitoring would not have been needed.
Advisory board recommendation
The participants agreed with initiation of de novo 
NOAC therapy in patients with a high thromboembolic 
risk (i.e., CHA2DS2-VASc score >3) without the war-
farin “challenge” process. The board also agreed with 
NOAC therapy instead of warfarin in NOAC-eligible 
AF patients in accordance with current guidelines.[54,69]
Summary
Due to the limited external validity of Phase III 
NOAC trials, clinicians are commonly faced with 
challenging patients who were underrepresented in 
these trials. This expert consensus of cardiologists 
aimed to define management strategies for some of 
these difficult cases using examples from their own 
experience. Although strong evidence is lacking, ex-
ploratory subgroup analysis of phase III pivotal trials 
can partially inform the management of these cases. 
One of the phase III trials, the ROCKET-AF trial, en-
rolled patients with a different profile in that there was 
a higher thromboembolic and bleeding risk, a larger 
percentage of secondary prevention patients, and a 
larger percentage of co-morbid situations, etc. To this 
extent, the ROCKET-AF trial has greater external va-
lidity than other phase III NOAC trials. The responses 
of clinicians to the expert consensus confirm the im-
portance of this issue. The advisory board recommen-
dations are summarized in Table 2.
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